Alkion BioInnovations

We are committed to revolutionising the market by delivering ready-to-use green alternatives for the modern-day farmer and grower, including:. We are not there yet but we are optimistic and determined to play a leading role in this vital change of direction. AlphaBio is committed to the development of plant protection solutions from natural and sustainable sources. AlphaBio is an award-winning company, having won the Green Apple Environmental Award for Environmental Best Practice in 2018, the Queens Award for Enterprise in 2021 and a Global Green Business Award in 2022. Underpinned by scientific research and rigorous testing, our products have levels of efficacy comparable to conventional market solutions. With a progressive research and development platform, AlphaBio has a pipeline of forward-looking products with safeguarding our biodiversity a key prerequisite in our thinking. Every innovation from AlphaBio is driven by a mission to deliver highly efficient biocontrol tools that look after our precious natural environment.

We are a young, research-intensive, microalgae biotechnology start-up. At Fykia, we develop innovative solutions, based on exclusive microalgae and proprietary technologies to tackle modern problems in healthcare, skincare and agriculture. We are based in the metro area of Porto, Portugal, a bustling hub for algal technology. Fykia Biotech's exclusive collection of rare microalgae strains is the basis of our R&D programme in cosmetics. Fykia harnesses the ancient power of algae to bring to the market new all-natural ingredients with anti-inflammatory, anti-oxidant and anti-ageing. Fykia Biotech uses a unique approach to develop sustainable fertilizers and plant growth stimulants. We provide tailor-made solutions based on the culture and soil to provide maximum output without harming the environment. Building up on years of R&D on obesity and related comorbidities, Fykia Biotech is developing antiobesogenic nutraceuticals from safe-to-eat microalgae.

Alkion operates nine bulk liquid storage terminals, strategically located in five major European economies: France, Portugal, Spain, Italy and the Netherlands. We are therefore focused on providing storage for chemicals, renewables and synthetic products, along with new logistics services such as tank container storage. Alkion terminals are integrated into numerous local, regional and national supply chains and markets. We are proud of the way in which our people continue to operate smoothly throughout the Covid crisis. Alkion’s logo is a lively and colourful bird that embodies a timeless heritage. Alkion has therefore moved quickly to offer the flexibility and capability that will enable them to produce, develop, source and blend a growing range of renewable fuels and chemicals. Alkion’s foresight and growing expertise in this area means that it is well positioned to meet this opportunity. Everything Alkion does is underpinned by six core values shared by everyone who works at Alkon :.

At Alvion, we are rethinking pharmaceuticals with a new business model that creates the pharmaceutical company of tomorrow. Alvion is a science oriented pharmaceutical company developing and manufacturing non infringing generic medicines in Europe. Collaborating with state of the art R&D centers in EU, Alvion is a private and independent company focusing in R&D, IP, Quality, Regulatory and manufacturing of generic and added value medicines, delivering an exceptional track record in the global pharmaceutical market supplying millions of patients. By developing a best-in-class international pharmaceutical company, Alvion is launching a wide portfolio of products and services across Europe, MENA, Canada, Australia, South Africa and Latin America partnering with some of the most well-known multinational pharmaceuticals companies. Out licensing of its proprietaries and supplying these medicines is the core business of the group, aiming to become the next unicorn in its industry in Europe. Developing and manufacturing noninfringing generic medicines in Europe. Developing, manufacturing, and promoting medicines in Europe, MENA, Canada, Australia, South Africa, Australia, Asia and Latin America is the core business model of Alvion. Focusing on delivering innovation and best quality pharmaceuticals among the first companies prior the patent expiry while offering flexible terms and affordable medicines with an effective supply chain is major competitive advantage of Alvion.

We, in Alkaloid, permanently strive to protect and preserve this precious gift of the nature. Alkaloid AD Skopje is a company which more than eight and a half decades, has been operating in the field of manufacturing drugs, cosmetic and chemical products and processing botanical raw materials. Alkaloid AD is a joint stock company that consists of two profit centers: Pharmaceuticals and Chemicals, Cosmetics and Botanicals; there are two subsidiaries in the country as well as 19 subsidiaries and 2 representative offices abroad (Serbia, Montenegro, Kosovo, Albania, Bosnia and Herzegovina, Croatia, Slovenia, Switzerland, Bulgaria, Turkey, Ukraine, the Russian Federation, USA ,UK and Romania). Alkaloid shares are owned by over 5,487 shareholders physical and legal entities. We are committed towards continuous improvement of human health that is reflected through our motto:. Alkaloid, as a globally oriented company, strives to accomplish high goals and achievements, which will enable high competitiveness and market positioning. We are constantly open to building new markets and new partnerships, production and placement of superior quality products, applying the latest technologies and business standards. We are convinced that ethical doing business is a prerequisite for constant personal and business success, and our key values are:.

We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders such as Alzheimer’s Disease. Aphios®, which means “virus-free” in Greek, was founded in 1993 as a Delaware C corporation. Aphios® initially focused on basic and applied research to develop its broad platform of enabling technologies, generate its intellectual property portfolio and initiate the establishment of a rich pipeline of ethical and over-the-counter (OTC) products. Aphios® has had partnerships/collaborations with Novartis, Basel, Switzerland and Cambridge, MA; Bayer, Research Triangle Park, NC; Bristol-Myers Squibb, Wallingford, CT and Princeton, NJ; Eli Lilly, Indianapolis, IN; Baxter Healthcare, Los Angeles, CA and Norwood, MA; Infinity Pharmaceuticals, Cambridge, MA; Instituto BioMar, Leon, Spain; VivaCell Biotechnology, Cordoba, Spain; Quiral, Juiz de Fora, Brazil; the Gillette Company (now Procter & Gamble), Boston, MA and other multinational and emerging biotechnology companies. We are seeking partners and investors to further the development and utilization of our enabling technology platforms and enhanced therapeutic products pipeline. We are interested in working with individuals and companies dedicated to improving quality of life, maintaining health and treating unmet medical needs. Aphios’ business model is designed to develop enabling technologies and enhanced therapeutics for maintaining health and resolving unmet medical needs while maximizing profitability and minimizing risks. Our mission is our passion: Sustainable, earth-friendly nanotechnologies and therapeutics for health maintenance and disease treatment.